ReviewNature2019
Harnessing innate immunity in cancer therapy.
Review in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 545 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
545 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Chemotherapy cardiotoxicity research in cancer patients: a bibliometric and visual analysis (1994-2024).Frontiers in oncology · 2025Pooled it
- Liquid-liquid phase separation drives immune signaling transduction in cancer: a bibliometric and visualized study from 1992 to 2024.Frontiers in oncology · 2025Pooled it
- Nanoadjuvant-based membrane poration boosts antitumor immunity via modulating mitochondrial metabolism to downregulate PD-L1 and upregulate STING.Bioactive materials · 2027Article
- Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy.Cell cycle (Georgetown, Tex.) · 2026Review
- Article
- Nanoengineered STING agonists for cancer therapy: toward immunodynamic control.Journal of hematology & oncology · 2026Review
- Carrier-free nanomodulators reprogramming acetate metabolism for cancer photo-immunotherapy via c-Myc inhibition-induced closed-loop regulatory circuit.Materials today. Bio · 2026Article
- Cell-based immunotherapy for neurodegenerative disease: A promising avenue.Neural regeneration research · 2026Article
- The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- Review
- Integrative Omics Analysis Reveals a CD206Barrier immunity · 2026Article
- Combined HER2-targeted mRNA-LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights.Bioengineering & translational medicine · 2026Article
- Formation of tertiary lymphoid structures drives Parkin antitumor immunity.Science advances · 2026Article
- Tumor-Infiltrating mregDCs Restrain Anti-Tumor Immunity in Early Relapse HCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Brucea Javanica Oil Attenuates Osteosarcoma Progression by Reprogramming Tumor-associated Macrophages via Inhibiting PI3K/AKT Pathway.Applied biochemistry and biotechnology · 2026Article
- The Dynamic Alliance of p53 and Metabolism in the Tumor Microenvironment Shapes Tumor Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Inhibiting CXCL12/CXCR4 axis enhances T cell activity in gastric cancer.Cancer gene therapy · 2026Article
- Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms.Science advances · 2026Article
- Multifunctional Manganese-Based Nanocomposites for Enhanced Immunotherapy by Regulating Lactate Metabolism and Activating the cGAS-STING Pathway.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
485 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodies. Although these therapies have led to unprecedented successes, only a minority of patients with cancer benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in the next generation of immunotherapy. Given the crucial role of innate immune responses in immunity, harnessing these responses opens up new possibilities for long-lasting, multilayered tumour control.
Indexed as
Identifiers
31578484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.